Akt signaling by cilostazol mitigates lipopolysaccharide-induced septic acute kidney injury

Ahmed F. Mohamed, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, EgyptFollow
Helmy M. Sayed, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt
Hala F. Zaki, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt
Marwa M. Safar, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt

Subject Area

Pharmacology and Clinical Pharmacy

Abstract

Cilostazol was investigated as a protective agent against lipopolysaccharide (LPS)-associated acute kidney damage in mice. Cilostazol (50 mg/kg/day; p.o) administered for 7 consecutive days before a single LPS dose (2 mg/kg; i.p) hampered serum creatinine and cystatin C as well as renal KIM-1 and NGAL, repressed TLR4 and MYD88 transcription as well as NF-κB p65, IL-1β and MDA content, boosted Nrf-2 mRNA expression, HO-1 activity and GSH content. This was synchronous with an upregulation of p-PI3K and p-Akt expressions. Collectively, cilostazol prevented LPS renal injury which might correspond to modulation of TLR4/NF-κB, Nrf2/HO-1 and PI3K/Akt pathways.

Recommended Citation

Mohamed, Ahmed F.; Sayed, Helmy M.; Zaki, Hala F.; and Safar, Marwa M. (2022) "Modulation of TLR4/NF-κB, Nrf2/HO-1 and PI3K/Akt signaling by cilostazol mitigates lipopolysaccharide-induced septic acute kidney injury," Bulletin of Faculty of Pharmacy Cairo University: Vol. 60 : Iss. 2 , Article 1.
Available at: https://doi.org/10.54634/2090-9101.1034